Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Evercore ISI upgraded shares of TXNM Energy (NYSE:TXNM – Free Report) from an in-line rating to an outperform rating in a ...

Evercore ISI analyst Chris McNally maintained a Buy rating on QuantumScape (QS – Research Report) yesterday and set a price target of $10.00.

In a report released yesterday, Durgesh Chopra from Evercore ISI maintained a Buy rating on Nisource (NI – Research Report), with a price ...